Tyme Technologies Inc. (TYME)

[axelvento]

Through the collaboration agreement, the companies may also evaluate oral SM-88 in combination therapy or as monotherapy by utilizing Eagle’s oncology pipeline and expertise in oncology settings.

The collaboration provides an opportunity for Tyme to expand its presence in the oncology space and evaluate potential combination opportunities with SM-88 in its existing pipeline. The partnership will also provide the company with commercial and capital resources required to fulfill this motive.
zero dilution